Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.08% | -39.31% | -23.70% | -43.75% | -22.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.94% | -22.75% | -57.17% | -60.18% | -49.77% |
| Operating Income | 38.59% | 29.93% | 66.65% | 65.21% | 49.77% |
| Income Before Tax | -341.39% | 27.85% | 64.98% | -10.59% | 48.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -341.39% | 27.85% | 64.98% | -10.59% | 48.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -341.39% | 27.85% | 64.98% | -10.59% | 48.18% |
| EBIT | 38.59% | 29.93% | 66.65% | 65.21% | 49.77% |
| EBITDA | 39.23% | 30.39% | 67.14% | 65.80% | 50.15% |
| EPS Basic | -43.75% | 54.92% | 78.86% | 25.26% | 51.89% |
| Normalized Basic EPS | -42.99% | 54.92% | 78.87% | 75.99% | 51.89% |
| EPS Diluted | -43.75% | 54.92% | 78.86% | 25.26% | 51.89% |
| Normalized Diluted EPS | -42.99% | 54.92% | 78.87% | 75.99% | 51.89% |
| Average Basic Shares Outstanding | 207.05% | 60.04% | 65.71% | 47.95% | 7.72% |
| Average Diluted Shares Outstanding | 207.05% | 60.04% | 65.71% | 47.95% | 7.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |